• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

    8/11/23 5:05:36 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email
    SC 13D/A 1 tm2323564d1_sc13da.htm SC 13D/A

     

     

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
         
      SCHEDULE 13D/A  

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*

     

    VOR BIOPHARMA INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    929033108

     

    (CUSIP Number)

     

    RA Capital Management, L.P.

    200 Berkeley Street, 18th Floor

    Boston, MA 02116

    Attn: Peter Kolchinsky

    Telephone: 617.778.2500

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    August 10, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   929033108
     
      1.

    Names of Reporting Persons.

    RA Capital Management, L.P.

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
     
      3. SEC Use Only
     
      4. Source of Funds (See Instructions)
    AF
     
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o
     
      6. Citizenship or Place of Organization
    Delaware
     
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
     
    8. Shared Voting Power
    22,780,343
     
    9. Sole Dispositive Power
    0
     
    10. Shared Dispositive Power
    22,780,343
     
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
    22,780,343
     
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
     
      13. Percent of Class Represented by Amount in Row (11)
    33.7%1
     
      14. Type of Reporting Person (See Instructions)
    IA, PN
               

     

     

    1 The Reporting Person is the beneficial owner of 22,748,880 shares of the Issuer’s Common Stock as well as shares underlying each of 30,525 vested stock options (right to buy) and 938 stock options (right to buy) which shall vest within 60 days of this filing held by Dr. Joshua Resnick for the benefit of RA Capital. The percentage calculation assumes that there are 67,570,143 outstanding shares of Common Stock of the Issuer, based on 67,538,680 outstanding shares of Common Stock of the Issuer as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 10, 2023, and giving effect to the stock options referenced herein.

     

     

     

     

    CUSIP No.   929033108
     
      1.

    Names of Reporting Persons.

    Peter Kolchinsky

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
     
      3. SEC Use Only
     
      4. Source of Funds (See Instructions)
    AF
     
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
     
      6. Citizenship or Place of Organization
    United States
     
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
     
    8. Shared Voting Power
    22,780,343
     
    9. Sole Dispositive Power
    0
     
    10. Shared Dispositive Power
    22,780,343
     
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
    22,780,343
     
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
     
      13. Percent of Class Represented by Amount in Row (11)
    33.7%2
     
      14. Type of Reporting Person (See Instructions)
    HC, IN
               

     

     

    2 The Reporting Person is the beneficial owner of 22,748,880 shares of the Issuer’s Common Stock as well as shares underlying each of 30,525 vested stock options (right to buy) and 938 stock options (right to buy) which shall vest within 60 days of this filing held by Dr. Joshua Resnick for the benefit of RA Capital. The percentage calculation assumes that there are 67,570,143 outstanding shares of Common Stock of the Issuer, based on 67,538,680 outstanding shares of Common Stock of the Issuer as reported in the Issuer’s Form 10-Q filed with the SEC on August 10, 2023, and giving effect to the stock options referenced herein.

     

     

     

     

    CUSIP No.   929033108
     
      1.

    Names of Reporting Persons.

    Rajeev Shah

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
     
      3. SEC Use Only
     
      4. Source of Funds (See Instructions)
    AF
     
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
     
      6. Citizenship or Place of Organization
    United States
     
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
     
    8. Shared Voting Power
    22,780,343
     
    9. Sole Dispositive Power
    0
     
    10. Shared Dispositive Power
    22,780,343
     
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
    22,780,343
     
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o
     
      13. Percent of Class Represented by Amount in Row (11)
    33.7%3
     
      14. Type of Reporting Person (See Instructions)
    HC, IN
               

     

     

    3 The Reporting Person is the beneficial owner of 22,748,880 shares of the Issuer’s Common Stock as well as shares underlying each of 30,525 vested stock options (right to buy) and 938 stock options (right to buy) which shall vest within 60 days of this filing held by Dr. Joshua Resnick for the benefit of RA Capital. The percentage calculation assumes that there are 67,570,143 outstanding shares of Common Stock of the Issuer, based on 67,538,680 outstanding shares of Common Stock of the Issuer as reported in the Issuer’s Form 10-Q filed with the SEC on August 10, 2023, and giving effect to the stock options referenced herein.

     

     

     

     

    CUSIP No.   929033108
     
      1.

    Names of Reporting Persons.

    RA Capital Healthcare Fund, L.P.

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a)  ¨
        (b)  ¨
     
      3. SEC Use Only
     
      4. Source of Funds (See Instructions)
    WC
     
      5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     ¨
     
      6. Citizenship or Place of Organization
    Delaware
     
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    7. Sole Voting Power
    0
     
    8. Shared Voting Power
    20,923,554
     
    9. Sole Dispositive Power
    0
     
    10. Shared Dispositive Power
    20,923,554
     
      11. Aggregate Amount Beneficially Owned by Each Reporting Person
    20,923,554
     
      12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   ¨
     
      13. Percent of Class Represented by Amount in Row (11)
    31%4
     
      14. Type of Reporting Person (See Instructions)
    PN
               

     

     

    4 The Reporting Person is the beneficial owner of 20,923,554 shares of the Issuer’s Common Stock. The percentage calculation assumes that there are 67,538,680 outstanding shares of Common Stock of the Issuer based on the Issuer’s Form 10-Q filed with the SEC on August 10, 2023.

     

     

     

    Item 1. Security and Issuer

     

    Item 1 of the Statement is hereby amended and supplemented as follows:

     

    This Amendment No. 3 (this “Amendment No. 3” or this “13D/A”) amends and supplements the statement on the Schedule 13D originally filed with the Securities and Exchange Commission (the “SEC”) on February 19, 2021, and amended on November 14, 20223, and December 9, 2022 (as amended, the “Statement”), filed by RA Capital Management, L.P., Dr. Kolchinsky, Mr. Shah, and RA Capital Healthcare Fund, L.P. with respect to the common stock, par value $0.001 per share (the “Common Stock”), of Vor Biopharma Inc., a Delaware corporation (the “Issuer”). Unless otherwise defined herein, capitalized terms used in this Amendment No. 4 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.

     

    Item 2.Identity and Background

     

    Item 2 of the Statement is amended and restated in its entirety to read as follows:

     

    (a)This 13D/A is being filed on behalf of RA Capital Management, L.P. (“RA Capital”), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the “Fund”), who are collectively referred to herein as the “Reporting Persons”.  The agreement among the Reporting Persons to file this 13D/A jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended (the “Act”), is attached hereto as Exhibit 1.

     

    The Reporting Persons ownership of the Issuer’s securities include (1) 20,923,554 shares of Common Stock held by the Fund, (2) 1,825,326 shares of Common Stock held by the RA Capital Nexus Fund, L.P. (the “Nexus Fund”), (3) a total of 30,525 vested stock options (right to buy) and (4) 938 stock options (right to buy) which shall vest within 60 days of this filing.

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund GP, LLC is the general partner of the Nexus Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and the Nexus Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the “Act”), of any securities of the Issuer held by the Fund or the Nexus Fund.  The Fund and the Nexus Fund have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s and the Nexus Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein.  Because the Fund and the Nexus Fund have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days’ notice, the Fund and the Nexus Fund disclaim beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital.  RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Statement other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    (b)The address of the principal business office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116.

     

    (c)The Fund is a private investment vehicle. RA Capital provides investment management services to the Fund and the Nexus Fund. The principal occupation of Dr. Kolchinsky and Mr. Shah is investment management.

     

    (d)During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)See Item 6 of the cover pages.

     

     

     

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Statement is hereby amended and restated in its entirety to read as follows:

     

    (a)The information set forth in rows 11 and 13 of the cover pages to this 13D/A is incorporated by reference.  The percentage set forth in row 13 is based on 67,538,680 outstanding shares of Common Stock, as reported by the Issuer in its Form 10-Q filed with the SEC on August 10, 2023.

     

    (b)The information set forth in rows 7 through 10 of the cover pages to this 13D/A and Item 2 above is incorporated by reference.

     

    (c)The following table lists the Reporting Persons’ transactions in Common Stock that were effected during the sixty day period to the filing of this 13D/A:5

     

    Transaction Purchaser Date No. Shares Price
    Vest Stock Option (Right to Buy) RA Capital 5-July-2023 469 (1)
    Vest Stock Option (Right to Buy) RA Capital 5-August-2023 469 (1)
    Vest Stock Option (Right to Buy) RA Capital 5-September-2022 469 (1)*
    Vest Stock Option (Right to Buy) RA Capital 5-October-2023 469 (1)*
    Vest Stock Option (Right to Buy) RA Capital 14-June-2023 16,911 (2)

     

    (1)    1/36th of the shares underlying the option vest in equal monthly installments commencing on March 5, 2021, provided that Dr. Joshua Resnick remains continuously engaged by the Issuer on each such vesting date.

     

    (2)    This option was granted to Joshua Resnick, a Managing Director of the Adviser who serves on the Issuer's board of directors, pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to Mr. Resnick's continuedservice as a director through such date.

     

    * Represents future vesting within 60 days from the filing date of this Schedule 13D/A.

     

    (d)No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this 13D/A.

     

    (e)Not applicable.

     

    Item 7. Material to be Filed as Exhibits

     

    Item 7 of the Statement is hereby amended and restated as follows:

     

    Exhibit 1        Joint Filing Agreement  

     

     

     

    5 The Common Stock and percentage ownership reported in this amendment reflect an increase in the number of outstanding shares of the Issuer. The vesting options in Item 5(c) did not cause a material change in the Reporting Persons’ beneficial ownership. 

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:August 11, 2023  
       
    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
    Name: Peter Kolchinsky  
    Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
    Name: Peter Kolchinsky  
    Title: Manager  

     

     

     

     

     

    Exhibit 1

     

    JOINT FILING AGREEMENT

     

    This Joint Filing Agreement, dated as of August 11, 2023, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”).

     

    Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or 13D with respect to Common Stock, par value $0.0001 per share of Vor Biopharma, Inc. beneficially owned by them from time to time.

     

    Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.

     

    This Joint Filing Agreement may be terminated by any of the Filers upon one week’s prior written notice or such lesser period of notice as the Filers may mutually agree.

     

    Executed and delivered as of the date first above written.

     

    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
    Name: Peter Kolchinsky  
    Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
    Name: Peter Kolchinsky  
    Title: Manager  

     

     

     

    Get the next $VOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    12/2/2021$30.00Outperform
    Oppenheimer
    10/19/2021$40.00Market Outperform
    JMP Securities
    More analyst ratings

    $VOR
    SEC Filings

    See more
    • Vor Biopharma Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Vor Biopharma Inc. (0001817229) (Filer)

      5/8/25 8:35:56 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFR14A filed by Vor Biopharma Inc.

      DEFR14A - Vor Biopharma Inc. (0001817229) (Filer)

      4/30/25 4:04:48 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Vor Biopharma Inc.

      8-K - Vor Biopharma Inc. (0001817229) (Filer)

      4/25/25 4:01:13 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Vor Biopharma with a new price target

      Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

      7/26/22 8:25:46 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Vor Biopharma with a new price target

      Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00

      4/27/22 6:14:19 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Vor Biopharma with a new price target

      HC Wainwright & Co. initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $26.00

      12/17/21 6:23:13 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      1/2/25 7:42:04 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    See more

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

      CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund. Mr. Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. Currently the Managing Member of

      1/8/25 9:00:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

      CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang. Dr. Choi brings to Vor Bio over twenty-five years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. His deep expertise in structuring corporate partnerships and investments, managing complex transact

      9/30/24 7:00:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

      CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board. In his role at Blueprint Medicines, Dr. Namouni has demonstrated exceptional leadership in building the company's fully integrated business and advancing a broad pipeline of innovative medicines to address significant medical needs in oncology/hematology and allergy/inflammation. With over two decades of experience in

      5/2/24 4:01:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

      5/8/25 8:30:15 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PureTech Announces Annual Results for Year Ended December 31, 2024

      Innovation engine drives meaningful clinical, regulatory, and financial milestones, including positive Phase 2b results for wholly-owned deupirfenidone (LYT-100) in IPF, compelling Phase 1b data for wholly-owned LYT-200 in AML and solid tumors, FDA approval of PureTech-invented Cobenfy™1 for schizophrenia, and rapid growth of Founded Entity2, Seaport Therapeutics, which raised over $325 million Capital-efficient operations support robust balance sheet with PureTech level cash, cash equivalents, and short-term investments of $366.8 million3 and consolidated cash, cash equivalents, and short-term investments of $367.3 million4 as of December 31, 2024, with operational runway into at least 20

      4/30/25 2:00:00 AM ET
      $PRTC
      $VOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

      VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025$55.6 million private placement completed in December 2024 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended December 31, 2024, and provided a business update.  "We continue to make significant strides in advancing our novel cell and genome engineering platform. The continued progress in our cl

      3/20/25 4:05:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT AND CEO Ang Robert covered exercise/tax liability with 2,361 shares, decreasing direct ownership by 0.26% to 911,318 units (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/7/25 4:05:57 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Sci Off & Head Tech Ops Chakraborty Tirtha covered exercise/tax liability with 876 shares, decreasing direct ownership by 0.40% to 217,416 units (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/7/25 4:05:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Choi Han Wook covered exercise/tax liability with 2,061 shares, decreasing direct ownership by 4% to 51,280 units (SEC Form 4)

      4 - Vor Biopharma Inc. (0001817229) (Issuer)

      5/2/25 4:30:56 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

      SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

      11/14/24 4:33:50 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

      SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

      2/14/24 4:17:24 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

      SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

      2/14/24 4:08:06 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VOR
    Financials

    Live finance-specific insights

    See more
    • Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

      CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

      5/8/25 8:30:15 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

      Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

      12/9/24 7:30:00 AM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

      Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind

      9/5/24 4:01:00 PM ET
      $VOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care